TCTR20170807003已完成4 期
A Study to Observe Pure Red Cell Aplasia (PRCA) Occurrence in Patients with Chronic Kidney Disease Who Used Hema-Plus (Recombinant Human Erythropoietin Alfa) at Ramathibodi Hospital
Apexcela Co., Ltd.0 个研究点目标入组 40 人开始时间: 2017年8月7日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 0 N/A (No limit) 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •Each patient included in the review must meet all of the following criteria to be in this study:
- •1.Presented with chronic kidney disease (CKD).
- •2.History of receiving Hema-Plus for at least 12 months during the study period.
排除标准
- •Patients who met inclusion criteria but their medical records are not available for access.
研究者
相似试验
Unknown
4 期
Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin AlfaRed-Cell Aplasia, PureRenal Insufficiency, ChronicNCT02648126The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)531
已完成
不适用
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal AnaemiaRenal AnemiaPregnancyLactationNCT01543477Pfizer4,501
已完成
不适用
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney FailurePure Red-Cell AplasiaChronic Kidney FailureNCT00391287Johnson & Johnson Pharmaceutical Research & Development, L.L.C.15,334
已完成
不适用
Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another ErythropoietinRed-Cell Aplasia, PureChronic Renal FailureNCT00210951Johnson & Johnson Pharmaceutical Research & Development, L.L.C.4,761
Unknown
4 期
Tacrolimus Treatment for Refractory PRCAPure Red Cell AplasiaNCT03540472Peking Union Medical College Hospital30